Obesity, Overweight, Type 1 Diabetes Mellitus
Conditions
Brief summary
This study employs a cross-sectional design to profile the gut microbiome and urine metabolome in overweight/obese children with type 1 diabetes (T1D).
Detailed description
The investigators will obtain stool and urine samples from subjects aged 7-17 years in 4 groups: * Group 1: Obese or overweight children within 3 years of diagnosis of T1D * Group 2: Normal weight children within 3 years of diagnosis of T1D * Group 3: Obese or overweight children without T1D * Group 4: Normal weight children without T1D Type 1 diabetes will be defined according to American Diabetes Association criteria along with the presence of pancreatic autoantibodies (GAD65, ICA512, or insulin autoantibodies). Obese and overweight status will be defined by BMI \>85th percentile for age and gender according to CDC criteria. All subjects will provide one-time stool and first morning urine sample. Overweight or obese subjects will additionally have a point of care blood glucose and hemoglobin A1c measurement to ensure that they do not have diabetes. The investigators will perform 16S rRNA sequencing of stool bacteria and mass spectrometry measurement of urine metabolites.
Interventions
OTHERNo intervention
No intervention
Sponsors
University of California, San Diego
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
7 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 7 to 17 years * Diagnosis of diabetes will be defined by current American Diabetes Association criteria ° (fasting glucose \> 126 mg/dl, 2 hour OGTT glucose \> 200 mg/dl; random glucose \> 200 with symptoms of hyperglycemia; or HbA1c \> 6.5%) * Diabetes duration \< 3 years * Presence of pancreatic autoimmunity (GAD65, ICA512, or insulin autoantibody positivity) * Adult caregiver willing to actively support study participation * Signed parental informed consent form and minor child informed assent form
Exclusion criteria
* Other significant organ system illness or condition (including psychiatric or developmental disorder) that, in the opinion of the investigator, would prevent participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of gut microbial composition and diversity by 16S rRNA sequencing | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of urine metabolite concentrations measured by mass spectrometry | 2 years |
Countries
United States
Outcome results
None listed